BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 17296813)

  • 21. Current trends in multimodality treatment of esophageal and gastroesophageal junction cancer - Review article.
    Klevebro F; Ekman S; Nilsson M
    Surg Oncol; 2017 Sep; 26(3):290-295. PubMed ID: 28807249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction.
    Ku GY; Ilson DH
    Expert Rev Anticancer Ther; 2008 Dec; 8(12):1953-64. PubMed ID: 19046115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What's the Best Way to Treat GE Junction Tumors? Approach Like Gastric Cancer.
    Mullen JT; Kwak EL; Hong TS
    Ann Surg Oncol; 2016 Nov; 23(12):3780-3785. PubMed ID: 27459983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus.
    Leers JM; DeMeester SR; Chan N; Ayazi S; Oezcelik A; Abate E; Banki F; Lipham JC; Hagen JA; DeMeester TR
    J Thorac Cardiovasc Surg; 2009 Sep; 138(3):594-602; discussion 601-2. PubMed ID: 19698841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer of the gastroesophageal junction: a diagnosis, classification, and management review.
    Chevallay M; Bollschweiler E; Chandramohan SM; Schmidt T; Koch O; Demanzoni G; Mönig S; Allum W
    Ann N Y Acad Sci; 2018 Dec; 1434(1):132-138. PubMed ID: 30138540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality.
    Fuentes E; Ahmad R; Hong TS; Clark JW; Kwak EL; Rattner DW; Mullen JT
    J Surg Oncol; 2016 Apr; 113(5):560-4. PubMed ID: 26792144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?
    Lin D; Khan U; Goetze TO; Reizine N; Goodman KA; Shah MA; Catenacci DV; Al-Batran SE; Posey JA
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e88-e95. PubMed ID: 31099690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution.
    Ruol A; Castoro C; Portale G; Cavallin F; Sileni VC; Cagol M; Alfieri R; Corti L; Boso C; Zaninotto G; Peracchia A; Ancona E
    Arch Surg; 2009 Mar; 144(3):247-54; discussion 254. PubMed ID: 19289664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Esophagogastric junction and gastric adenocarcinoma: current challenges and future directions.
    Saba NF
    Oncology (Williston Park); 2014 Jun; 28(6):520-1. PubMed ID: 25134327
    [No Abstract]   [Full Text] [Related]  

  • 30. Outcome after esophagectomy for cancer of the esophagus and GEJ in patients aged over 75 years.
    Internullo E; Moons J; Nafteux P; Coosemans W; Decker G; De Leyn P; Van Raemdonck D; Lerut T
    Eur J Cardiothorac Surg; 2008 Jun; 33(6):1096-104. PubMed ID: 18407509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastroesophageal junction carcinoma multimodal treatment: standards, debate and new therapeutic options.
    Liakakos T; Katsios C; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2011 Feb; 5(1):1-4. PubMed ID: 21309665
    [No Abstract]   [Full Text] [Related]  

  • 32. Combination chemoradiation therapy: the whole is more than the sum of the parts.
    Mamon HJ; Tepper JE
    J Clin Oncol; 2014 Feb; 32(5):367-9. PubMed ID: 24419110
    [No Abstract]   [Full Text] [Related]  

  • 33. Reply to E. C. Smyth et al.
    Hulshof MC; Oppedijk V; van der Gaast A
    J Clin Oncol; 2014 Sep; 32(27):3081-2. PubMed ID: 25071131
    [No Abstract]   [Full Text] [Related]  

  • 34. Reply to E. C. Smyth et al.
    Mamon HJ; Tepper JE
    J Clin Oncol; 2014 Sep; 32(27):3082. PubMed ID: 25071102
    [No Abstract]   [Full Text] [Related]  

  • 35. Adenocarcinoma at the gastroesophageal junction.
    Al-Haddad S; Chang AC; De Hertogh G; Grin A; Langer R; Sagaert X; Salemme M; Streutker CJ; Soucy G; Tripathi M; Upton MP; Vieth M; Villanacci V
    Ann N Y Acad Sci; 2014 Sep; 1325():211-25. PubMed ID: 25266027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesophageal junction are correlated with early cancer recurrence: role of systematic grading of complications using the modified Clavien classification.
    Lerut T; Moons J; Coosemans W; Van Raemdonck D; De Leyn P; Decaluwé H; Decker G; Nafteux P
    Ann Surg; 2009 Nov; 250(5):798-807. PubMed ID: 19809297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer.
    Ruol A; Portale G; Castoro C; Merigliano S; Cagol M; Cavallin F; Chiarion Sileni V; Corti L; Rampado S; Costantini M; Ancona E
    Ann Surg Oncol; 2007 Nov; 14(11):3243-50. PubMed ID: 17713823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histopathologic classification of adenocarcinoma of the esophagogastric junction.
    Baldus SE
    Recent Results Cancer Res; 2010; 182():29-38. PubMed ID: 20676869
    [No Abstract]   [Full Text] [Related]  

  • 39. For localized gastroesophageal cancer, you give chemoradiation before surgery, but then what happens?
    Ajani JA; Correa AM; Swisher SG; Wu TT
    J Clin Oncol; 2007 Sep; 25(27):4315-6. PubMed ID: 17878485
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment results of adenocarcinoma of the gastroesophageal junction.
    Yonemura Y; Kojima N; Kawamura T; Tsukiyama G; Bandou E; Sakamoto N; Tsubosa Y; Sato H
    Hepatogastroenterology; 2008; 55(82-83):475-81. PubMed ID: 18613391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.